The QualityStocks Daily Thursday, February 18th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(VYCO) +148.88%

MarketClub Analysis(GTEC) +95.23%

StockHideout(SPONF) +38.36%

The QualityStocks Daily Stock List

Aphria Inc. (NASDAQ: APHA)

InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, MarketBeat, The Street, Daily Trade Alert, Trades Of The Day, Wealth Insider Alert, StreetInsider, The Online Investor, Kiplinger Today, StockMarketWatch, Top Pros' Top Picks, Investopedia, CFN Media Group, BUYINS.NET, Money Morning, Stock Up Featured, Zacks, Inside Trading, StreetAuthority Daily, Daily Profit, Trading Concepts and QualityStocks reported earlier on Aphria Inc. (APHA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aphria Inc. (NASDAQ: APHA) is engaged in the production, supply and sale of recreational and medicinal cannabis. The company operates using the following segments; Business Under Development, Distribution Operations and Cannabis Operations. While the Business Under Development segment deals with firm operations that have not received final approval or have not begun commercial sales, the Cannabis Operations segment deals with producing, selling and distributing both adult-use and medical marijuana.

Aphria, which was founded in 2013 by John Cervini and Cole Cacciavillani, is based in Leamington, Canada. The firm operates through wholesale and retail channels in Canada as well as internationally in countries like Argentina, Colombia, Italy, and Malta. The company is Germany’s main distributor of medical marijuana.

Aphria Inc.’s marijuana operations are made up of its Aphria One greenhouse and other facilities which are held through the company’s Aphria Diamond and Broken Coast Cannabis Ltd. subsidiaries. The firm’s greenhouse facility is located at its headquarters while the indoor marijuana production facility managed by its Broken Coast Cannabis Ltd subsidiary is located on Vancouver Island. The latter provides B.C. Bud’s marijuana brands in Canada.

Aphria Inc. offers products such as cannabis oil with dried cannabis, in addition to marijuana-derived extracts and derivative marijuana products under its Broken Coast, B!NGO, Aphria, Good Supply, RIFF and Solei brands. The company’s Distribution Operations segment are executed through its subsidiaries like CC Pharma, FL Group and ABP. Another subsidiary of the company, Avanti Rx Analytics Inc., offers testing services to its Canadian marijuana operations and also processes, packages, labels and tests cannabis oil and dried marijuana for medicinal use.

Focused on boosting international cultivation and distribution of the world’s medical marijuana market, Aphria recently announced that it would merge with Tilray, another Canadian cannabis company, to create the world’s biggest marijuana firm. This could mean hefty returns for the company’s shareholders and stakeholders and a very bright future for the firm, particularly on its growth and expansion.

Aphria Inc. (APHA), closed Thursday’s trading session at $19.23, off by 6.6958%, on 37,080,811 volume with 433 trades. The average volume for the last 3 months is 22,392,065 and the stock's 52-week low/high is $1.95000004/$32.2900009.

Canopy Growth Corporation (NYSE: CGC; NASDAQ: WEED)

InvestorPlace, The Street, Schaeffer's, Trades Of The Day, MarketClub Analysis, MarketBeat, Daily Trade Alert, The Online Investor, Kiplinger Today, Wealth Insider Alert, Streetwise Reports, StocksEarning, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, Stock Up Featured, StreetAuthority Daily, StockEarnings, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, QualityStocks, Lebed.biz, SeriousTraders, StockMarketWatch, Wall Street Grand, Profit Trends, Money Morning, Jim Cramer, CNBC Breaking News, Cannabis Financial Network News, Louis Navellier, BUYINS.NET, Inside Trading, StocksToBuyNow, Outsider Club and Trading For Keeps reported earlier on Canopy Growth Corporation (CGC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Canopy Growth Corporation (NYSE: CGC; NASDAQ: WEED) is a diversified marijuana company. Through its subsidiaries Tweed Farms Inc., Bedrocan Canada Inc. and Tweed Inc., the firm engages in the business of growing and selling legal cannabis in the medical cannabis market of Canada. The company also produces and sells cannabis in Canada’s recreational marijuana market.

The company, which was formerly known as Tweed Marijuana Inc. before being renamed in 2015, operates through 2 segments; Canopy Rivers and Cannabis, Hemp and other consumer products. Canopy Growth has 2 core brands, Bedrocan and Tweed. The Bedrocan brand is all about medical grade marijuana, which is planted on a more than 52,000ft2 facility in Toronto while Tweed is a licensed producer of medical cannabis.

Canopy Growth has its headquarters in Smiths Falls, Canada. While the company’s primary operations are in Canada, it also operates in the United Kingdom, Germany and the United States and has production and distribution licenses in more than 12 nations to help extend the use of medical marijuana worldwide. The company was founded in 2013 by Bruce Linton and Chuck Rifici.

The company provides products which include hemp, dried marijuana flowers, concentrates and oils and soft gel capsules. Canopy Growth is also focused on finding treatments for the loss of appetite, treatment of chronic pain, nausea, muscle spasms and seizures. The firm’s products are offered under different Canopy Growth’s brands, such as Bean & Bud, DOJA, First & Free, Tokyo Smoke, Tweed, This Works, Van der Pop, Spectrum Therapeutics, TWD and Deep Space.

Canopy Growth has already strengthened its presence in the Canadian market and in addition to the immense research it’s conducting, the company will soon be making a killing in the markets with the U.S. cannabis markets set to expand in the near future. Its Acreage Holdings Inc. acquisition in the U.S. may see the firm dominating the marijuana market for some time to come.

Canopy Growth Corporation (CGC), closed Thursday’s trading session at $36.65, off by 9.4167%, on 8,193,577 volume with 66 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $9.00/$56.4964981.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)

StockMarketWatch, MarketBeat, Streetwise Reports, QualityStocks, TopPennyStockMovers, BUYINS.NET, TraderPower, Jason Bond, MarketClub Analysis, OTCtipReporter, PennyStockProphet, PennyStockScholar, PoliticsAndMyPortfolio, Promotion Stock Secrets, Wall Street Mover, Stock Beast, The Online Investor, Trader Power News and Profitable Trader Authority reported previously on Diffusion Pharmaceuticals Inc. (DFFN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is a biotechnology firm that is focused on developing treatments for various life-threatening medical conditions such as treatment-resistant solid cancerous tumors.

The firm is also centered on improving the efficacy of the present-day standard-of-care treatments, which include chemotherapy and radiation therapy. Diffusion Pharmaceuticals was founded in 2001 by John L. Gainer and David G. Kalergis. The firm serves customers and patients in the United States and is based in Charlottesville, Virginia.

Diffusion Pharmaceuticals also has a collaboration research agreement with the Integrated Translational Research Institute of Virginia and the University of Virginia Health, to assess trans sodium crocetinate in patients who have COVID-related acute respiratory distress syndrome.

Diffusion Pharmaceuticals Inc.’s lead candidate is trans sodium crocetinate (TSC), which was developed for use in the various cancer types which are affected by tumor hypoxia. The oxygen deprivation is known to reduce the efficacy of present-day treatments. TSC, which is currently in its Phase 3 trials for glioblastoma multiforme (GBM) treatment, also has applications in indications involving oxygen deprivation, such as neurodegenerative ailments and stroke. Additionally, the compound is undergoing phase 2 clinical trials for metastatic brain cancer treatment and the treatment of acute stroke.

A phase 2 clinical trial, concluded in 2015, showed favorable efficacy and safety profiles for trans sodium crocetinate combined with standard of care. Diffusion Pharmaceuticals Inc.’s lead candidate has shown therapeutic potential by safely re-oxygenating different types of tumors, which demonstrates its usefulness in improving the standard-of-care treatments for many cancers. This has been the foundation of discussions with the FDA and with a phase 3 program for GBM on the way, a treatment may not be far behind and the future of the company looks bright.

Diffusion Pharmaceuticals Inc. (DFFN), closed Thursday’s trading session at $1.44, off by 3.3557%, on 12,867,786 volume. The average volume for the last 3 months is 6,310,481 and the stock's 52-week low/high is $0.25/$1.85000002.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)

MarketBeat, StockMarketWatch, Kiplinger Today, StreetInsider, Marketbeat.com, InvestorPlace, QualityStocks, MarketClub Analysis, TraderPower, BUYINS.NET, Daily Trade Alert, Flagler Financial Group, Planet Penny Stocks, Buzz Stocks, Penny Pick Finders, OTCtipReporter, Penny Stock 101, PennyStockScholar, Profitable Trader Authority, Schaeffer's, Stock Gumshoe, Stock News Now, StockOnion, StockOodles, StreetAuthority Daily, TopStockAnalysts and PennyStockProphet reported beforehand on Galmed Pharmaceuticals Ltd. (GLMD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a biopharmaceutical firm which is engaged in the development and commercialization of oral therapy treatments of inflammatory, metabolic and liver diseases such as cholesterol gallstones and non-alcoholic steatohepatitis (NASH).

Galmed Pharmaceuticals was founded in 2000 by Tuvia Gilat and Allen Baharaff. Mr. Baharaff has served as the firm’s CEO since 2012 and its President from 2015. The firm is part of the Scientific Research and Development Services Industry in the country and has its headquarters in Tel Aviv-Jaffa, in Israel.

The company provides its products to medical and healthcare industries. Galmed Pharmaceuticals Ltd developed a synthetic bile-acid/fatty-acid conjugate, known as Aramchol. The compound, which is an ailment modifying treatment for fatty liver disorders, is the drug candidate for treating fibrosis and NASH in an ongoing Phase 3 ARMOR study. The compound has demonstrated that it can improve metabolic parameters linked to NASH while also decreasing liver fat content.

As of early 2021, Galmed Pharmaceuticals Ltd had published their findings from their phase 3 ARMOR study on the efficacy of Aramchol, after their discovery confirmed that Aramchol could potentially be used to treat non-alcoholic steatohepatitis patients who have fibrosis.

There are currently no medicines approved to treat non-alcoholic steatohepatitis. Galmed Pharmaceuticals Ltd. being the first to find an effective treatment would open up doors to more research into their candidates, which would earn the firm a lot of opportunities as well as investments.

Galmed Pharmaceuticals Ltd. (GLMD), closed Thursday’s trading session at $4.52, up 0.892857%, on 550,933 volume with 2 trades. The average volume for the last 3 months is 315,078 and the stock's 52-week low/high is $2.96000003/$6.40000009.

Sunshine Biopharma, Inc. (SBFM)

QualityStocks, Investor Ideas, PennyStocks24, Ceocast News, Stock Twiter, OTCPicks, Gorilla Stock Trades, Pennybuster, Jet-Life Penny Stocks, AllPennyStocks, Fast Money Alerts, FeedBlitz, Greenbackers, Investor Stock Alerts, Ironman Stock, MassiveStockProfits, 007 Stock Chat, Otcstockexchange, Winston Small Cap, Penny Stock General, PennyStockSpy, Shiznit Stocks, Stock Roach, Stock Shock and Awe, StockHideout, Whisper from Wall Street and Mina Mar Marketing Group reported earlier on Sunshine Biopharma, Inc. (SBFM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma, Inc. is a pharmaceutical company listed on the OTC Markets. The Company concentrates on the development of drugs for the treatment of aggressive types of cancer. Furthermore, Sunshine offers generic pharmaceuticals, Essential Brand dietary supplements, and certified analytical chemistry services. Sunshine Biopharma has its corporate office in Pointe-Claire, Quebec.

The Company operates by way of three subsidiaries. These comprise Atlas Pharma, Inc. (Testing Services); Sunshine Biopharma Canada, Inc. (Generic Drugs); and NOX Pharmaceuticals, Inc. (Propriety Drugs). Atlas Pharma offers certified testing services of pharmaceutical and other industrial samples. Generic drugs coming soon from Sunshine Biopharma Canada (not available in the U.S.) include SBI-Anastrozole for treatment of Breast Cancer; SBI-Letrozole for treatment of Breast Cancer; SBI-Bicalutamide for treatment of Prostate Cancer; and SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia).

Regarding Sunshine Biopharma’s Proprietary Drugs in development, the Company’s flagship anticancer drug is Adva-27a. This is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for different kinds of cancer. The expectation is that Adva-27a will enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection.

Sunshine Biopharma also has its dietary supplements product line - Essential 9™. This product contains all 9 essential amino acids in one tablet for maintaining and building muscle mass.

Sunshine Biopharma has also announced it signed an agreement with Crocus Laboratories Inc., (Montreal) for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine Biopharma in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a. The material, which will ultimately be generated by a contract manufacturing organization, will be used for animal toxicity studies and clinical trials.

Recently, Sunshine Biopharma announced it launched 7 new dietary supplements in addition to its original product, Essential 9™. The new products are BCAA; L-Carnitine; L-Creatine; L-Glutamine; Vitaminax; Omega 3; and Vitamin B12.

Sunshine Biopharma, Inc. (SBFM), closed Thursday’s trading session at $0.23, up 26.3736%, on 6,413,796 volume. The average volume for the last 3 months is 8,549,808 and the stock's 52-week low/high is $0.0013/$0.944500029.

Jupiter Gold Corporation (JUPGF)

We reported  previously on Jupiter Gold Corporation (JUPGF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Jupiter Gold Corporation has 100 percent-ownership in a number of gold projects aggregating more than 154,000 acres in Brazil in the development and exploratory stages. The Company has six projects and 11 mineral rights and acreage in some of the best gold provinces in Brazil. In addition, it owns a completely operational gold recovery plant in Brazil, now placed in a mining concession. The plant employs centrifugation for recovery of particulate gold. Jupiter Gold is headquartered in Belo Horizonte, Brazil. The Company’s shares trade on the OTC Markets’ OTCQB.

Jupiter Gold’s two flagship projects are (i) the Alpha Gold Project, with greater than 22,000 acres of mineral rights for gold in the State of Minas Gerais; and the Alta Floresta Gold Project, with 24,610 acres of mineral rights for gold in the State of Mato Grosso. Both of these projects are presently under geological exploration by the Company.

Jupiter Gold’s projects are situated in premier gold provinces in Brazil. These include Paracatu (where the largest gold mine in the nation is located, owned by international giant Kinross Gold; 16 million ounces of gold mined and in reported reserves; annual production of 480,000 ounces); and Crixás (with four gold mines owned by gold giant AngloGold Ashanti; 7 million ounces of gold mined and in reported reserves; annual production of 130,000 ounces).

Furthermore, the Company’s projects are located in the Iron Quadrangle (numerous gold mines); and Serrita (known gold deposits and prospector activity). Also, they are positioned in the Amazon (a new gold frontier with potential for large mineralization).

Recently, Jupiter Gold announced that it filed with the Brazilian mining department the application for an initial mining license for its 100 percent-owned quartzite deposit in the State of Minas Gerais, Brazil. In July of this year, it was searching for gold in one of its properties and identified a large quartzite formation.

Subsequently, Jupiter Gold promptly proceeded with a number of geological field studies that confirmed the quality of the deposit and indicated the potential for 3.7 million tons of quartzite. Jupiter Gold stated that it is planning a simple open pit operation that could become profitable within a few months.

Jupiter Gold Corporation (JUPGF), closed Thursday’s trading session at $1.84, up 15.00%, on 4,000 volume. The average volume for the last 3 months is 4,655 and the stock's 52-week low/high is $0.200000002/$2.25.

Driven Deliveries, Inc. (DRVD)

TradersPro reported previously on Driven Deliveries, Inc. (DRVD), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Driven Deliveries, Inc. is California's fastest growing online cannabis retailer and direct-to-consumer delivery company. It is the first United States-based publicly traded cannabis delivery service operating within the USA. The Company previously went by the name Results-Based Outsourcing, Inc. It changed its name to Driven Deliveries, Inc. in September of 2018. Ganjarunner is a subsidiary of Driven Deliveries. Established in 2013, Driven Deliveries is headquartered in San Diego, California. The Company lists on the OTC Markets Group’s OTCQB.

Driven Deliveries provides e-commerce solutions, online sales, and on-demand cannabis delivery in select cities where permitted by law. It provides legal cannabis consumers the ability to purchase and receive their marijuana in a speedy and convenient manner. Driven Deliveries provides a proprietary, turnkey delivery system to its customers.

The Company works with brands and their products to be the all-in-one delivery solution to the States of California, Nevada, and Oregon. Driven Deliveries enables brands to sell and deliver their products directly to consumers via e-commerce and home delivery solutions. It connects upstream cultivators, manufacturers, brands, as well as retailers through software and logistics solutions. The Company covers 92 percent of California's population for next day and almost 60 percent same day. It delivers to urban, rural, and metropolitan areas and homes, businesses, and hotels.

Driven Deliveries earlier successfully launched its new brand to consumer program, BrandBudee. This solution enables brands to sell directly to consumers by way of their own website, shopping products available to purchase based on their location. BrandBudee provides consumers direct access to some of the most renowned cannabis brands in the space with delivery in less than 90 minutes across California.

Recently, Stem Holdings, Inc. announced it signed a Definitive Agreement to acquire Driven Deliveries, Inc. The expectation is that the Acquisition will close in late calendar year 2020 as an all-stock transaction.

This acquisition by Stem Holdings of all of the stock of Driven Deliveries will create what Stem believes will be the first vertically-integrated cannabis company with an integrated Delivery as a Service (DaaS) platform to meet the increasing market for medical and adult-use cannabis home delivery with best-selling and disruptive new products.

Driven Deliveries, Inc. (DRVD), closed Thursday’s trading session at $0.80, even for the day. The stock's 52-week low/high is $0.238000005/$1.53999996.

Progressive Care, Inc. (RXMD)

SmallCapVoice, QualityStocks, PennyStocks24, Marketbeat.com, PennyPickAlerts, The Observer, StockMister, Bull Trends, Stock News Now, SeeThruEquity Research, StockMarketQuote.us, Top Stock Picks, 1-2-3 Stock Alerts, Penny Stock Circle, MarketClub Analysis, Information Solutions Group, Fortune Stock Alerts, DreamTeamNetwork and PennyPro reported previously on Progressive Care, Inc. (RXMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Progressive Care, Inc. is a personalized healthcare services and technology company listed on the OTC Markets. Its business model is to create an interconnected system between doctors, patients, insurances, pharmacies, and caregivers. Established in 2005, Progressive Care has its corporate headquarters in Hallandale Beach, Florida.

Via its subsidiaries, the Company is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

PharmCo Rx is a subsidiary of Progressive Care. PharmCo’s dedication is to providing effective, timely, and affordable medications. PharmCo is a full-service pharmacy. On June 1, 2019, PharmCo Rx and FSRx (Five Star Rx) became one company, delivering same-day delivery to all of its patients.

Moreover, Progressive Care will develop and produce proprietary cannabinoid and homeopathic products that will be exclusively offered from RXMD Therapeutics, Inc. The first line of production will consist of tinctures, skin creams, roll-ons, and gel capsules that are the dosage forms most easily managed by retail patients.

Recently, Progressive Care announced its April 2020 Performance. The Company said it continued strong growth amid a challenging context. Consolidated Monthly Gross Sales across all locations totaled $2.97 million. This represents year-over-year growth of 54 percent versus April 2019. Prescriptions filled during the month came in at 41,637. This represents year-over-year growth of 45 percent versus April 2019. Progressive Care continues to expand its recently launched new COVID-19 IgG/IgM rapid result antibody testing program.

Recently, Progressive Care announced that it chose Atlas Construction and Management LLC for the construction project at 400 Ansin Blvd in Hallandale Beach, Florida. It has started the work to consolidate its North Miami Beach and Davie locations into a single large-scale pharmacy operation. The expectation is that this consolidation will facilitate cost savings of over $300K, which will be realized in Q1 2021 financial data.

Progressive Care, Inc. (RXMD), closed Thursday’s trading session at $0.11, up 23.0425%, on 17,160,016 volume. The average volume for the last 3 months is 2,857,500 and the stock's 52-week low/high is $0.022749999/$0.119999997.

Beyond Commerce, Inc. (BYOC)

QualityStocks, Stockpalooza, Stock Stars, Penny Stock Finder, PennyStockLive, Otcstockexchange, MicroStockProfit, Mega Stock Pick, StockHideout, Whisper from Wall Street, Bullish Stock Picks, HotOTC, Free Hot Penny Stocks, Early Bird, Penny Stock MoneyTrain, CoolPennyStocks, Momentum Traders, Nebula Stocks, BullRally, NYStockReport, OTC Stock Review, Penny Invest, Liquid Tycoon, Stock Guru, Winning Penny Stock Picks, We Pick Penny Stocks, Wallstreetlivechat, The PennyStock Picks, Super Nova Stock Picks, Super Hot Penny Stocks, Penny Stock Pick Report, Stock Rich, Penny Stock Pick Alert, Round Up the Bulls, Real Pennies, Promotion Stock Secrets, Premiumstockpicks, Wise Alerts, PennyTrader Publisher, Bull Warrior Stocks and StockEgg reported previously on Beyond Commerce, Inc. (BYOC), and today we choose to report on the Company once again, here at the QualityStocks Daily Newsletter. 

Beyond Commerce, Inc. is a planned provider of B2B (Business to Business) internet marketing analytics, technologies, and related services. The Company’s planned objective is to develop, acquire, and deploy disruptive strategic software technology that will build on organic growth potential. Additionally, its planned goal is to exploit cross-selling opportunities. Beyond Commerce is based in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company operates as a holding enterprise that focuses on “big data” companies in the global B2B Internet Marketing Analytics/Technology and Services space. Beyond Commerce plans to provide a cohesive digital product and services platform. This is to provide clients with a single point of contact for their big data, marketing and related sales initiatives. The Company’s emphasis is to develop, acquire, and also deploy disruptive strategic software technology and market-changing business models through acquisition or organic growth.

Beyond Commerce previously announced that it was added to the LD Micro Index effective August 1, 2018. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said at that time, "This is an exciting time for us as we continue to execute on business milestones which are translating into additional exposure in the capital markets and building on our goals for corporate transparency and credibility with stakeholders. LD Micro has championed the microcap space and I am proud that we have been included in their index and to be recognized with other successful peers in the microcap space."

Recently, Beyond Commerce announced that it signed a definitive business combination agreement with PathUX, LLC. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said, "PathUX provides Cloud based marketing automation software and will make a great addition to our future vision, has recurring revenues and a great team.

Beyond Commerce, Inc. (BYOC), closed Thursday’s trading session at $0.0075, up 92.3077%, on 694,092,865 volume. The average volume for the last 3 months is 77,232,707 and the stock's 52-week low/high is $0.00025/$0.008799999.

Wize Pharma, Inc. (WIZP)

We reported beforehand on Wize Pharma, Inc. (WIZP), and today we highlight the Company again, here at the QualityStocks Daily Newsletter.

Wize Pharma, Inc. focuses on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The OTCQB-listed Company previously went by the name Star Night Technologies Ltd. It changed its corporate name to Wize Pharma, Inc. in July of 2015. A clinical-stage biopharmaceutical enterprise, the Company is headquartered in Hod Hasharon, Israel.

Wize Pharma has in-licensed certain rights to purchase, market, sell, and distribute a formula named LO2A. This is a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome. Currently, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

Wize Pharma is now conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. The Company announced in March of last year that it enrolled the initial patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. This randomized, double-masked study is evaluating LO2A versus Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes.

The design of the study (in addition to meeting marketing approval requirements in Israel) is to support Wize Pharma’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine. LO2A is already approved in Israel for the treatment of DES.

This past November, Wize Pharma announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh). Wize Pharma's Chairman, Noam Danenberg, stated, "We are very pleased with these top line results and we look forward to analyzing the full results. We believe the full results from this study, will support our clinical development path and provide firm basis for presentation and discussions with the FDA for the approval pathway of LO2A in the U.S. and additional countries."

Recently, Wize Pharma announced that it signed an agreement with Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) to form a joint venture (JV) company for researching, developing and administering cannabinoid formulations to treat ophthalmic conditions. Cannabics Pharmaceuticals is a global leader in personalized cannabinoid medicine centered on cancer and its side effects.

This agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids. Upon effectiveness, Wize Pharma shall issue 900,000 shares of its common stock to Cannabics Pharmaceuticals. Cannabics shall issue 2,263,944 shares of its common stock to Wize.

Wize Pharma, Inc. (WIZP), closed Thursday’s trading session at $1.01, up 17.4419%, on 531,730 volume. The average volume for the last 3 months is 103,406 and the stock's 52-week low/high is $0.061/$1.20000004.

El Capitan Precious Metals, Inc. (ECPN)

QualityStocks, BullRally, CoolPennyStocks, HotOTC, PennyTrader Publisher, StockEgg, Stock Rich, OTCPicks, AllPennyStocks, PennyStockVille, FeedBlitz, HyperGrowthStock, MadPennyStocks, Penny Invest, PennyStockVideos, Xtremepicks, Pumps and Dumps, SmallCapVoice, Stock Traders Chat, StockRich, TopPennyStockMovers and PennyInvest reported beforehand on El Capitan Precious Metals, Inc. (ECPN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is a mining company based in Scottsdale, Arizona.  It mainly engages in the mining of precious metals and other minerals. The Company chiefly holds interest in the El Capitan gold-silver property situated  close to Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals’ principal asset is its wholly-owned subsidiary El Capitan, Ltd., an Arizona corporation.

The El Capitan, Ltd. subsidiary holds the 100 percent equity interest in the El Capitan property. The Company’s primary objective is the sale of the El Capitan property. 

The El Capitan deposit has been known as a potential iron ore resource for numerous decades. The El Capitan deposit has a near-surface, pervasive nature. All of this takes place above the regional water table. This provides the potential for a low mining cost and a long life operation.

El Capitan Precious Metals owns 3,840 acres of mining property in Lincoln County. This includes 80 acres of patented and 3,760 acres of leased property. These include 188 mining claims. The El Capitan property encompasses 354 Bureau of Land Management (BLM) lode claims and four patented claims.  

El Capitan Precious Metals has enhanced its relationship with Logistica US by way of an agreement under which El Capitan will provide to Logistica concentrated ore to their specifications at the mine site. Logistica will transport, process, as well as refine the precious metals concentrates to sell to precious metals buyers. The agreement is in addition to and complements the previously announced agreement for the sale of iron ore for use in construction. 

Previously, El Capitan Precious Metals announced that it entered into an agreement with a refiner that will buy, refine, and sell the hyper-concentrates generated by the pilot plant. Moreover, the Company reported that the refiner has spent a considerable amount of time with its contract miner at the pilot plant and at the mine site.

El Capitan Precious Metals also announced that an agreement for the sale of the Company’s precious metal hyper-concentrates. El Capitan Chairman and Chief Executive Officer, Mr. John F. Stapleton reported that El Capitan reached a final agreement with a buyer and executed a Purchase Agreement for all remaining hyper-concentrates produced by the Pilot Plant from the concentrate materials stored at the bonded warehouse in Tucson, Arizona.

El Capitan Precious Metals, Inc. (ECPN), closed Thursday’s trading session at $0.0096, up 20.00%, on 292,034 volume. The average volume for the last 3 months is 661,253 and the stock's 52-week low/high is $0.003599999/$0.0215.

Tautachrome, Inc. (TTCM)

We are reporting on Tautachrome, Inc. (TTCM), here at the QualityStocks Daily Newsletter.

Tautachrome, Inc. is an emerging growth enterprise in the developing digital imagery technology sector. It is a developer of software applications for trustable and engageable digital pictures and videos. The Company’s chief priority is developing its branded KlickZie platform. An Internet technology development business, Tautachrome is headquartered in Oro Valley, Arizona and has operations in the United States and Australia.

The KlickZie platform will turn smartphones into trusted imagers. This means the pictures and videos they capture can be verified as original, untampered,  and un-photoshopped. Additionally, the KlickZie platform creates imagery that is interactive and engageable.

The KlickZie platform will serve as the world’s first imagery-based social website network. Through clicking or tapping on a KlickZie'd image, users can communicate with the image's author or others presently looking at the image, in an engaging way.

Basically,  KlickZie is an image verification service for smartphones. It brings trust back to digital imagery. In addition, KlickZie turns the smartphone into a reliable image source. Smartphone users download KlickZie’s free software to take their pictures and videos.

KlickZie pictures and videos are invisibly marked, stored in the KlickZie cloud, and guaranteed free from manipulation. The cloud will certify the authenticity of any KlickZie picture or video.

Tautachrome also has pioneering patents pending. These include Talk-to-the-Picture social networking and the abovementioned trustable imagery-based interaction.

Tautachrome is establishing a development team of providers to develop a blockchain based cryptocurrency ecosystem with a cryptotoken designated “KLK”. It will be the currency of the KlickZie community internationally.

This will permit KlickZie users to monetize their pictures and videos. As a result, it will enable the buying, selling, and licensing of KlickZie pictures and videos everywhere.

Recently, Tautachrome announced that it hired the Pryor Cashman law firm in New York to lead its work to register its KLK cryptotoken sale with the Securities and Exchange Commission (SEC). Mr. Ali Panjwani with support from his colleagues Mr. Jeff Alberts and Mr. Mike Campoli is leading the Pryor Cashman work team.

This team has considerable cryptotoken knowledge. In addition, it has significant experience with SEC registration. This includes past employment with the SEC in this area.

Tautachrome Chief Executive Officer, Dr. Jon N Leonard, said, “I have directed the Pryor Cashman team to work with the SEC’s crypto currency task force to ensure that our vision for a KLK cryptotoken-based ecosystem, able to monetize the world’s smartphone imagery becomes a reality, and that it is fully compliant with SEC regulations. We appear to be breaking new ground in this work. But I believe that the social and economic potential of this effort is so great, that every effort is justified.”

Tautachrome, Inc. (TTCM), closed Thursday’s trading session at $0.0113, up 41.25%, on 73,004,986 volume. The average volume for the last 3 months is 12,741,612 and the stock's 52-week low/high is $0.0019/$0.0175.

Vycor Medical, Inc. (VYCO)

Wall Street Resources, QualityStocks, FeedBlitz, PennyStockScholar, OTCtipReporter and MarketBeat reported previously on Vycor Medical, Inc. (VYCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vycor Medical, Inc. is a provider of distinct and first-class surgical and therapeutic solutions. The Company operates two business units - Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has U.S. Food and Drug Administration (FDA) 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan, Russia, and Taiwan. Vycor Medical is based in Boca Raton, Florida.

The Company’s NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight because of stroke or brain injury. The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. This helps improve and partially restore sight in patients with neurological vision impairments.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for quicker, safer, and also more economical brain surgeries, as well as faster patient discharge.

The design of VBAS is to optimize neurosurgical site access and reduce patient risk. In addition, the design of VBAS is to expedite recovery and add tangible value to the professional medical community.

The Company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss.

Vycor Medical has developed NeuroEyeCoach™. This is a therapy that is highly complementary to VRT™. NeuroEyeCoach™ is a compensation therapy registered in the United States as a Class I 510(k) exempt device. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently. NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder due to a stroke or brain injury.

Vycor Medical, Inc. (VYCO), closed Thursday’s trading session at $0.278, up 148.8809%, on 232,861 volume. The average volume for the last 3 months is 21,363 and the stock's 52-week low/high is $0.0102/$0.50999999.

Momo Inc. (NASDAQ: MOMO)

MarketClub Analysis, InvestorPlace, Schaeffer's, StocksEarning, Marketbeat, Market Intelligence Center Alert, The Street, Kiplinger Today, Zacks, StreetInsider, The Street Report, Marketbeat.com, StockEarnings, Trades Of The Day, Daily Trade Alert, BUYINS.NET, INO.com Market Report, QualityStocks, Wealth Insider Alert, StreetAuthority Daily, Trading Concepts, Louis Navellier, TopStockAnalysts, The Online Investor, Money Morning, Greenbackers, Street Insider, Daily Wealth, Investopedia, PennyDoctor, StockMarketWatch and StocksImpossible reported previously on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

  • Powerfully diverse Chinese social media and entertainment conglomerate Momo is finding a measure of renewed optimism following a pandemic-delivered economic blow to its businesses during the past year
  • Momo operates social connectivity services, online dating facilitation and TV and radio production interests
  • The company’s social connection streams provide a useful service during the social distancing strictures imposed by governments striving to contain the spread of the COVID-19 virus
  • Momo has seen a positive response to changes in its top leadership during the past year as part of its efforts to redefine its strategy

Chinese mobile-based social networking giant Momo Inc. (NASDAQ: MOMO) continues to regain momentum from COVID pandemic-induced difficulties during the past year, seeing new options become available (https://ibn.fm/nI0JK), share prices rise (https://ibn.fm/772H8) and its appeal increasing generally with investors (https://ibn.fm/KMArq) during recent weeks.

Momo has operated in three primary service line segments since its launch in 2011 and its Nasdaq Stock Exchange listing in 2014, most notably its Momo social interaction platform, which makes it easier for people to connect with each other as they identify similar geographical and lifestyle interests (https://ibn.fm/UmWmX). Tantan, one of the country’s top dating platforms, gained wide recognition as “China’s Tinder” (https://ibn.fm/vpnbT), and QOOL Media operates a diversified radio and TV production business (https://ibn.fm/UojBD).

Momo’s operations have allowed it to gather information from its users’ activities to create a comprehensive database of their social interests and match users on the basis of demographics such as age, gender, location, group membership, discussion interests and other social relationships. While helping people to meet based on such interests, the platform’s engine also is able to push advertising content to users based on their interests, with the idea that social context makes business promotion more relevant to users and less of an interruption to their experience.

The global COVID-19 pandemic has had an enormous impact on people’s ability to interact with each other socially, particularly in regions where governments have imposed strict restrictions in an effort to limit the transmission of the highly contagious virus. China was the first country to identify the health emergency, and as such was at the leading edge of experimental efforts to stop the virus’ spread (https://ibn.fm/ctE67).

Social media outlets such as those operated by Momo provide a means of helping people to continue to interact with each other even while separated by such measures. As the company’s multibillion-dollar revenue stream begins to rebound from the pandemic’s economic effects, its mobile applications and hosted recreational activities are enabling users to discover new relationships, expand social connections and build meaningful day-to-day interactions.

The company saw some of its top leadership positions change last year as part of its effort to regroup and rebuild its base, helping to drive a renewed sense of optimism (https://ibn.fm/lP7ji).

For more information on Momo Inc., visit the company’s Investor Relations web page at https://momoinc.gcs-web.com.

Momo Inc. (MOMO), closed Thursday’s trading session at $18.46, off by 4.8454%, on 6,187,677 volume. The average volume for the last 3 months is 5,360,981 and the stock's 52-week low/high is $12.5200004/$31.9799995.

The QualityStocks Company Corner

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic on the nation’s mental health (https://ibn.fm/ukaIx). These rising numbers, as well as the treatment for mental health illness and disorders, is of great concern to VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medications that goes beyond the standard of care for anxiety and depression. Also today, the company was highlighted in a publication from PennyStocks.com, examining how Jefferies analysts slapped a Buy on the stock along with a $6 price target. This puts the VTGN stock forecast over 190% higher than current levels based on Wednesday’s closing price. What’s more, this new rating came after VistaGen announced its latest round of earnings results. The company also updated its expected clinical studies this year relating to its central nervous system treatment pipeline.

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Thursday’s trading session at $2.48, up 20.3883%, on 34,371,521 volume. The average volume for the last 3 months is 3,526,719 and the stock's 52-week low/high is $0.300000011/$2.94000005.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Increasing patient demand for and clinical data in support  of blue light cystoscopy’s value in detecting to bladder cancer is shining new light on Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, and the potential value of their proprietary technology, the patented i/Blue Imaging System. Also today, the company was highlighted in a publication from InvestorWire, examining how IMEXF today announced that, further to its press releases of Oct. 22 and Nov. 10, 2020, it has closed the second tranche in the amount of US$1,415,500 of the convertible note offering. To view the full press release, visit http://ibn.fm/n3zDE

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Thursday’s trading session at $0.686324, up 0.91516%, on 24,784 volume. The average volume for the last 3 months is 45,906 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), a diversified company with a focus on technologies for the entertainment industry, has announced that its subsidiary Intercept Music Inc. has added two label members to its Artist Incubator program. Intercept, a marketing and distribution company with a focus on technologies for the entertainment industry, provides the artist intubator program to help develop emerging recording artists who want to sign with a music label. Through the program, labels that refer artists stay in touch with the artist by way of Intercept Music's advanced performance analytics. Intercept’s new label partners are Reggae Runnins and Division Street Music Group. To view the full press release, visit http://ibn.fm/QTzq4

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Thursday’s trading session at $0.0191, even for the day, on 341,550 volume. The average volume for the last 3 months is 858,191 and the stock's 52-week low/high is $0.0035/$0.100000001.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ:SRAX), a digital marketing pioneer focused on providing consumer data management services, recently revealed that Sequire, its investor intelligence SaaS platform, had grown to having over 3 million retail investors on its platform (https://ibn.fm/AzKzM). Launched as a stand-alone platform in early 2020, Sequire has seen its growth accelerate at an astounding rate – with the mix of investors and traders currently using its platform rising from 1 million to 3 million in a matter of mere months. The company has also attracted over 91 publicly-listed companies as subscribers on its platform (https://ibn.fm/5ZKtk) – an explosion of growth largely driven by Sequire’s extensive range of services.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday’s trading session at $5.63, off by 13.3846%, on 913,448 volume. The average volume for the last 3 months is 565,329 and the stock's 52-week low/high is $1.50999999/$7.19500017.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) was featured today in a publication from MiningNewsWire, examining how the constant rise in demand for exhaustible natural resources has attracted the interest of many nations globally, with many hoping to potentially harvest resources from outer space. Recently, a pair of professors from Western University launched a project whose objective is to tackle the gaps in the laws that govern mining in space and how these regulations may influence the companies and countries that would like to venture into the business of space mining. Additionally, the company was featured in a MiningNewsBreaks from MiningNewsWire, examining how EXN has announced diamond drilling results from a new discovery at its Silver City Project 2020 drill program. The Silver City Project is located in Saxony, Germany, and the results are with assays from an additional eight holes still outstanding. To view the full press release, visit https://ibn.fm/jGmLB

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Thursday’s trading session at $3.08, off by 1.9108%, on 73,297 volume. The average volume for the last 3 months is 71,800 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. To view the full press release, visit: https://ibn.fm/qNRoS

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday’s trading session at $3.06, off by 6.422%, on 615,001 volume. The average volume for the last 3 months is 2,628,804 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from PsychedelicNewsWire, examining how Massachusetts General Hospital is partnering with Atai Life Sciences to study the effects of psychedelics on the human brain. Atai Life Sciences is a biotech firm focused on developing medications to manage schizophrenia while also working on creating alternative treatments for various mental health conditions such as anxiety and depression.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Thursday’s trading session at $1.56, off by 2.50%, on 462,989 volume. The average volume for the last 3 months is 506,400 and the stock's 52-week low/high is $0.0284/$2.23499989.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. To view the full press release, visit: https://ibn.fm/9Rw9l

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday’s trading session at $1.93, off by 12.2727%, on 12,502,685 volume. The average volume for the last 3 months is 3,733,245 and the stock's 52-week low/high is $0.629999995/$4.42000007.

Recent News

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0).

MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) was featured today in a publication from BioMedWire, examining how results from various studies conducted by leading research institutions in the Unites States have found that wearables such as smartwatches, which measure an individual’s heart rate, also possess the ability to identify whether a person is coronavirus positive — even before symptoms start showing or the virus is detected using a test.

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.

Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions.

MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share.

TerraMG and Pipeline

The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide.

There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds.

MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases.

In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more.

The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form.

Currently, MustGrow’s pipeline also includes:

  • TerraMG, a pre-plant soil bio-pesticide, for:
    • Fruit & Vegetable – currently in Phase 4
    • Turf & Ornamental – currently in Phase 4
    • Tobacco – currently in Phase 4
    • Potatoes – currently in Phase 4
    • Canola – targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
    • Bananas – targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
    • Pulse Crops – targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
  • Non-Selective Bio-Herbicide – targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
  • Storage Bio-Pesticide for Bulk Grain, Fresh Produce – targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
  • Storage Bio-Pesticide for Shipping Containers – targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
  • Bio-Pesticide for Foodborne Pathogens – targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity

The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances.

Management Team

Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan.

Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD.

Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant.

Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan.

MustGrow Biologics Corp. (OTCQB: MGROF), closed Thursday’s trading session at $1.61, off by 3.012%, on 15,520 volume. The average volume for the last 3 months is 62,361 and the stock's 52-week low/high is $0.124499998/$1.87.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) was featured today in a publication from Green Car Stocks, examining how electric vehicles (“EVs”) are still too expensive for the average buyer. Although EVs are poised to ultimately replace internal combustion vehicles as countries around the world strive to reduce carbon emissions, improve air quality and achieve climate goals, the initial purchase costs put them out of the reach of most households. To make them more affordable and boost EV adoption, authorities in several countries have been offering subsidies, incentives and tax credits for certain electric vehicle purchases.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Thursday’s trading session at $1.5871, off by 3.6428%, on 142,239 volume. The average volume for the last 3 months is 220,406 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF).

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company that focuses on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelics sector, recently entered into two substantial cannabis biomass purchase agreements (https://cnw.fm/XYzBs) in addition to announcing that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States (https://cnw.fm/WO928). Also today, the company was featured in a publication from PsychedelicNewsWire, examining how PRXTF has signed an agreement with Canada House Wellness Group (CSE: CHV) to distribute concentrate products through existing provincial distribution channels. Canada House Wellness is a fully integrated medical cannabis company. The two companies have entered into a Cannabis 2.0 distribution agreement. The agreement notes that Canada House's wholly owned subsidiary Abba Medix Corp. will carry and distribute Pure Extracts' line of concentrate products. Canada House’s leadership team noted that it was impressed with the Pure Extracts team and the brand presence that Pure Extracts has established, specifically in the country’s Western provinces. To view the full press release, visit https://ibn.fm/jcc0t

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (PRXTF), closed Thursday’s trading session at $0.54295, off by 4.7456%, on 221,763 volume. The average volume for the last 3 months is 170,325 and the stock's 52-week low/high is $0.438603997/$1.00.

Recent News

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF)

The QualityStocks Daily Newsletter would like to spotlight Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF).

Josemaria Resources (TSX: JOSE) (OTC: JOSMF), a natural resources company offering an advanced-stage copper-gold deposit project located in Argentina, is a rare find in a junior mining company. This positions Josemaria well as junior mining companies may be what investors are looking for in terms of high-growth potential, according to a recent report released by VanEck (https://ibn.fm/lHJp0). To view the full article, visit https://ibn.fm/AxTAO.

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF) is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project.

Josemaria Resources is part of The Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors all around the world.

The Josemaria Copper-Gold Project

The company’s flagship Josemaria Copper-Gold Project is located in the San Juan Province of Argentina – a well-known mining hub supporting a wide variety of mining service companies. The Lundin Group has been active in Argentina for approximately 30 years. Committed to advancing the project, Josemaria Resources has already begun the bridging phase, with basic and detailed engineering planning expected to commence in early 2021.

The company recently announced the results of a feasibility study at the Josemaria Project. The study, prepared by a team of engineering and consulting providers including Fluor Canada Ltd., SRK Consulting (Canada) Inc. and Knight Piésold Ltd., highlights a robust, low-risk project with rapid payback expected via an open pit operation with forecast capacity to feed a conventional process plant at a rate of 152,000 tonnes a day over a 19-year mine life.

According to the feasibility study, the project is expected to yield an average annual production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver. Other highlights of the study include:

  • The optimized mining production plan provides average grades in the first three years of production that are notably better than the life-of-mine average. This supports a forecast 3.8-year payback period from the start of production.
  • The project’s total initial cost, including engineering, procurement, construction, management, on- and off-site infrastructure, contingency and pre-construction engineering work, amounts to roughly $3.09 billion.
  • The location provides readily available access to essential resources, including water, grid power, transportation and logistics infrastructure within San Juan Province.
  • An Environmental and Social Impact Assessment (ESIA) of the project is already underway and is expected to be submitted to relevant authority agencies for review during Q1 2021.

The Josemaria Copper-Gold Project has been designed to incorporate the latest technology. Per the feasibility study, the project will include the use of autonomous trucks and production drill fleets, with the option of incorporating green energy, indicating the company’s commitment to minimizing and mitigating the adverse effects of mining on the environment.

To this end, the company intends to leverage suitable planning, impact assessment and monitoring tools while also incorporating water and energy efficiency systems and ecosystem conservation services in the design and implementation of its operations.

Josemaria Resources President and CEO Adam Lundin welcomed the results of the study as confirming that this is one of the very few readily developable copper-gold projects in the world and forecasting an attractive economic outcome for the asset, comparable with other copper-gold projects in development.

“We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction,” Lundin said in a news release.

Market Outlook

The global smart mining market was estimated at $6.8 billion in 2019. It is forecast to reach $20.31 billion by 2025. The significant increase is expected to be driven by technological advancements within the sector.

Global demand for copper is also growing steadily, due to the metal’s versatility and multiple uses for industrial, domestic and high-technology indications. The global copper market is expected to reach $222.1 billion by the end of 2026.

Management Team

Adam Lundin is the President, CEO and Director of Josemaria Resources. He has several years of experience in managing capital markets and public companies across the natural resources sector. His background includes oil, gas, mining technology, investment advising, international finances and executive management. Lundin began his career working for several of the Lundin Group mining companies. He is currently engaged in multiple roles, as he is also the Chairman for Filo Mining Corp. and Africa Energy Corp. and a Director of NGEx Minerals Ltd. and the Lundin Foundation.

Ian Gibbs serves as CFO of Josemaria Resources. He is a Canadian Chartered Accountant and a graduate of the University of Calgary, holding a Bachelor of Commerce degree. Gibbs has held many prominent positions within the Lundin Group of companies over the last 15 years, most recently as the CFO of Africa Oil Corp.

Arndt Brettschneider is the company’s Vice President of Projects. He has over 23 years of international mining, consulting and project development experience. Before joining Josemaria Resources, he was Vice President of the mining consulting businesses of two globally recognized engineering companies. Brettschneider obtained a Bachelor of Science with Honors from the University of Queensland in Brisbane, Australia. He received his MBA from Queen’s University in Ontario, Canada.

Bob Carmichael is the company’s Vice President of Exploration. He joined Josemaria Resources from Lundin Mining Corporation’s UK office. In his UK role, he was the General Manager of Resource Exploration. Carmichael is a registered Professional Engineer in the Canadian province of British Columbia. He obtained a Bachelor of Applied Science from the University of British Columbia. His dual role includes serving as Vice President of Exploration for Filo Mining Corp. and NGEx Minerals Ltd.

Alfredo Vitaller is Josemaria Resources’ General Manager in Argentina. He has been involved in the mining industry since 1993. He graduated as a Licentiate in Geological Sciences from Buenos Aires University and has an M.Sc. from Mackay School of Mines at the University of Reno. Vitaller has worked with the Lundin Group since 1993 and was a part of the exploration teams for Filo, Helados and Josemaria.

Notable Directors

Ashley Heppenstall, chairman of the Josemaria Resources board of directors, has over 30 years of experience in the oil and gas and resources sectors. From 2002 to 2015, Heppenstall served as the President, CEO and Finance Director of Lundin Petroleum AB, an oil and gas exploration and production company with core assets in Norway and Southeast Asia. He is credited with building Lundin Petroleum into the largest independent oil firm in the world today, leveraging a single equity raise of $50 million to guide Lundin in the design and implementation of a strategy that’s led it to a current market cap of roughly $6 billion.

Ron Hochstein has worked for the Lundin family directly as a consultant for over 20 years and is currently the President and CEO of Lundin Gold, a gold-producing business whose key asset is the Fruta del Norte gold deposit in Ecuador. Hochstein led construction efforts on the first mine in Ecuador, which went into production in 2019 and was completed on time and on budget.

Paul Conibear has been with The Lundin Group for over two decades, including serving as the CEO and Director of Lundin Mining from 2011 through 2018. Lundin Mining’s current market cap is estimated at $3.5 billion. In total, Conibear has more than 35 years of experience in progressively more responsible positions in the resource sector ranging through management of all phases of mine investment, including exploration, economic assessments, construction, operations and closure.

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF), closed Thursday’s trading session at $0.538792, off by 3.0339%, on 6,785 volume. The average volume for the last 3 months is 15,865 and the stock's 52-week low/high is $0.465299993/$0.685000002.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

The direct-selling space is fast evolving. A recent article published in “Direct Selling News” highlights seven top trends impacting the speed and direction of that change (https://ibn.fm/dajuy). Operating in the health and wellness direct-selling industry, Sharing Services Global (OTCQB: SHRG) looks well placed to leverage most of those trends and securing a strong position in the new direct-selling era.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Thursday’s trading session at $0.25, off by 11.0004%, on 249,998 volume. The average volume for the last 3 months is 153,771 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed California-based cannabis company, today updated its recent announcement that it has been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction. The discussions have evolved to include development of a memorandum of understanding (“MOU”) that sets forth terms under which the parties could enter into a joint venture to jointly manufacture, distribute and market Grapefruit’s products. To view the full press release, visit: https://cnw.fm/Fa1QE. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Thanks to a new bill advancing in the Iowa Senate, Iowans may soon be paying only $10 every year in medical cannabis license fees instead of the $100 a year they currently pay. The bill will also allow the licensing of more medical cannabis dispensaries beyond the five currently allowed by law as well as the creation of mobile dispensaries to cater to the state’s medical marijuana patients. Additionally, Senate Bill 1177 will allow medical cannabis dispensaries to recommend physicians who can prescribe medical cannabis to patients, something current law prohibits.

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Thursday’s trading session at $0.2198, off by 6.8644%, on 3,646,898 volume. The average volume for the last 3 months is 1,756,175 and the stock's 52-week low/high is $0.013624999/$0.310000002.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading